martes, 23 de mayo de 2017

Myelodysplastic syndromes (MDS): percentage of higher-risk MDS patients receiving azacitidine or decitabine. | National Quality Measures Clearinghouse

Myelodysplastic syndromes (MDS): percentage of higher-risk MDS patients receiving azacitidine or decitabine. | National Quality Measures Clearinghouse

nqmc

American Society of Hematology

No hay comentarios: